Supplemental Table 2.

FGF21 levels across subjects according to sarcopenia and type 2 diabetes mellitus (DM) status

	Pre-intervention sarcopenic subjects (Mean±SD)/median(P_{25}, P_{75})			Post-intervention sarcopenic subjects (Mean±SD)/median(P_{25}, P_{75})			Non-sarcopenic subjects (Mean±SD)/median(P_{25}, P_{75})		
	total	DM[a]	non-DM	total	DM	non-DM	total	DM	non-DM
FGF21 pg/ml (P^* value)	49.99 (46.4,61.2) p_1=0.610	48.21 (46.3, 51.1) p_1=0.273	52.25 (46.4,63.0) p_1=1.000	53.80 (46.1.59.3) p_2=0.124	49.02 (45.7,58.5) p_2=0.333	53.91 (46.1,59.7) p_2=0.300	58.00 (50.1,68.9) p_3=0.150	82.99[b] p_3=0.333	56.31 (49.1,63.9) p_3=0.483

[a] the sample size was small for all diabetes subjects; DM, diabetes mellitus; FGF21, Fibroblast growth factor 21;

[b] there was only one sample in this category;

[*] The P_1 value represents the significance of differences between pre- and post- intervention, the P_2 value represents the significance of differences between post-intervention sarcopenic and non-sarcopenic elderly subjects, and the P_3 value represents the significance of differences between pre-intervention sarcopenic and non-sarcopenic elderly subjects. P value was calculated by Mann-Whitney U test.